These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 21854342)
1. Effects of inhaled mometasone furoate on growth velocity and adrenal function: a placebo-controlled trial in children 4-9 years old with mild persistent asthma. Skoner DP; Meltzer EO; Milgrom H; Stryszak P; Teper A; Staudinger H J Asthma; 2011 Oct; 48(8):848-59. PubMed ID: 21854342 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of mometasone furoate administered once-daily in the evening in patients with persistent asthma dependent on inhaled corticosteroids. D'Urzo A; Karpel JP; Busse WW; Boulet LP; Monahan ME; Lutsky B; Staudinger H Curr Med Res Opin; 2005 Aug; 21(8):1281-9. PubMed ID: 16083538 [TBL] [Abstract][Full Text] [Related]
3. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chrousos GP; Ghaly L; Shedden A; Iezzoni DG; Harris AG Chest; 2005 Jul; 128(1):70-7. PubMed ID: 16002918 [TBL] [Abstract][Full Text] [Related]
4. Effects of mometasone furoate given once daily in the evening on lung function and symptom control in persistent asthma. Karpel JP; Busse WW; Noonan MJ; Monahan ME; Lutsky B; Staudinger H Ann Pharmacother; 2005 Dec; 39(12):1977-83. PubMed ID: 16264062 [TBL] [Abstract][Full Text] [Related]
6. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. Kemp JP; Berkowitz RB; Miller SD; Murray JJ; Nolop K; Harrison JE J Allergy Clin Immunol; 2000 Sep; 106(3):485-92. PubMed ID: 10984368 [TBL] [Abstract][Full Text] [Related]
7. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Nayak AS; Banov C; Corren J; Feinstein BK; Floreani A; Friedman BF; Goldsobel A; Gottschlich GM; Hannaway PJ; Lampl KL; Lapidus RJ; Lawrence M; Lumry W; Munk Z; Pearlman D; Scardella AT; Schenkel EJ; Segal AT; Segall N; Silverman B; Shneyer L; Nolop KB; Harrison JE Ann Allergy Asthma Immunol; 2000 Apr; 84(4):417-24. PubMed ID: 10795650 [TBL] [Abstract][Full Text] [Related]
8. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Noonan M; Karpel JP; Bensch GW; Ramsdell JW; Webb DR; Nolop KB; Lutsky BN Ann Allergy Asthma Immunol; 2001 Jan; 86(1):36-43. PubMed ID: 11206236 [TBL] [Abstract][Full Text] [Related]
9. Mometasone furoate has minimal effects on the hypothalamic-pituitary-adrenal axis when delivered at high doses. Affrime MB; Kosoglou T; Thonoor CM; Flannery BE; Herron JM Chest; 2000 Dec; 118(6):1538-46. PubMed ID: 11115437 [TBL] [Abstract][Full Text] [Related]
10. Use of mometasone furoate administered via a dry powder inhaler in the treatment of asthma. Zeidler M; Corren J; Tashkin DP Curr Med Res Opin; 2010 Jun; 26(6):1295-305. PubMed ID: 20370376 [TBL] [Abstract][Full Text] [Related]
11. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. Kosoglou T; Cutler DL; Staudinger H; Herron JM Chest; 2010 Jan; 137(1):115-21. PubMed ID: 19749003 [TBL] [Abstract][Full Text] [Related]
12. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Skoner DP; Gentile DA; Angelini B Allergy Asthma Proc; 2010; 31(1):10-9. PubMed ID: 20167141 [TBL] [Abstract][Full Text] [Related]
13. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. Corren J; Berkowitz R; Murray JJ; Prenner B Int J Clin Pract; 2003 Sep; 57(7):567-72. PubMed ID: 14529054 [TBL] [Abstract][Full Text] [Related]
14. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. O'Connor B; Bonnaud G; Haahtela T; Luna JM; Querfurt H; Wegener T; Lutsky BN Ann Allergy Asthma Immunol; 2001 Apr; 86(4):397-404. PubMed ID: 11345282 [TBL] [Abstract][Full Text] [Related]
15. Effects of treatment with mometasone furoate dry powder inhaler in children with persistent asthma. Berger WE; Milgrom H; Chervinsky P; Noonan M; Weinstein SF; Lutsky BN; Staudinger H Ann Allergy Asthma Immunol; 2006 Nov; 97(5):672-80. PubMed ID: 17165278 [TBL] [Abstract][Full Text] [Related]
16. Hypothalamic-pituitary-adrenal axis effects of mometasone furoate/formoterol fumarate vs fluticasone propionate/salmeterol administered through metered-dose inhaler. Kosoglou T; Hubbell J; Cutler DL; Johnson-Levonas AO; Xu D; Kantesaria BS; Kim K; Miller SD Chest; 2013 Dec; 144(6):1795-1802. PubMed ID: 24077095 [TBL] [Abstract][Full Text] [Related]
17. Inhaled mometasone furoate improves health-related quality of life in patients with persistent asthma. Karpel J; D'urzo A; Lockey RF J Asthma; 2008 Nov; 45(9):747-53. PubMed ID: 18972289 [TBL] [Abstract][Full Text] [Related]
18. Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate. Nathan RA; Nayak AS; Graft DF; Lawrence M; Picone FJ; Ahmed T; Wolfe J; Vanderwalker ML; Nolop KB; Harrison JE Ann Allergy Asthma Immunol; 2001 Feb; 86(2):203-10. PubMed ID: 11258691 [TBL] [Abstract][Full Text] [Related]
19. Mometasone furoate antagonizes AMP-induced bronchoconstriction in patients with mild asthma. Holgate ST; Arshad H; Stryszak P; Harrison JE J Allergy Clin Immunol; 2000 May; 105(5):906-11. PubMed ID: 10808170 [TBL] [Abstract][Full Text] [Related]
20. Long-term safety of mometasone furoate administered via a dry powder inhaler in children: Results of an open-label study comparing mometasone furoate with beclomethasone dipropionate in children with persistent asthma. Noonan M; Leflein J; Corren J; Staudinger H BMC Pediatr; 2009 Jul; 9():43. PubMed ID: 19594937 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]